Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- ADARx Pharmaceuticals, Inc.
- Study ID
- NCT06990269
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ADX-038 — DRUGsiRNA duplex oligonucleotide
- Placebo — DRUGSaline
Study Details
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Key Dates
- Start date
- Nov 10, 2025
- Status verified
- Apr 2026
- Primary completion
- Feb 28, 2030
- Completion
- Aug 30, 2030
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Active - ADX-038
- Placebo Comparator: Placebo - Saline
Primary Outcome Measure
Evaluate the effect of ADX-038 on the preservation of the EZ layer [ Time Frame: 12 months ]
Central Contacts
- Nali Castillo877-232-7974
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| ADARx Clinical Site | Gilbert | Arizona | 85297 | - |
| ADARx Clinical Site | Phoenix | Arizona | 85020 | - |
| ADARx Clinical Site | Beverly Hills | California | 90211 | - |
| ADARx Clinical Site | Huntington Beach | California | 93647 | - |
| ADARx Clinical Site | Poway | California | 92064 | - |
| ADARx Clinical Site | Orlando | Florida | 32806 | - |
| ADARx Clinical Site | Wildwood | Florida | 34785 | - |
| ADARx Clinical Site | Hagerstown | Maryland | 21740 | - |
| ADARx Clinical Site | Reno | Nevada | 89502 | - |
| ADARx Clinical Site | Erie | Pennsylvania | 16505 | - |
| ADARx Clinical Site | Austin | Texas | 78705 | - |
| ADARx Clinical Site | Dallas | Texas | 75231 | - |
| ADARx Clinical Site | McAllen | Texas | 78503 | - |
| ADARx Clinical Site | Round Rock | Texas | 78681 | - |
| ADARx Clinical Site | San Antonio | Texas | 78340 | - |
| ADARx Clinical Site | The Woodlands | Texas | 77384 | - |
| ADARx Clinical Site | St. George | Utah | 84790 | - |
Find similar trials in Gilbert, AZ
Related Studies
- Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular DegenerationRecruiting · i-Lumen Scientific AUS PTY LTD · Manchester, Connecticut
- A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)Recruiting · Complement Therapeutics · Mountain View, California
- A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioPHASE2 · Recruiting · Apellis Pharmaceuticals, Inc. · Gilbert, Arizona
- An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)PHASE1/PHASE2 · Recruiting · Complement Therapeutics · Carmel, Indiana